600521 華海藥業
按盤價 
24.620 +0.310 (+1.275%) | 2025/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 4,516,354 | -11.93% | 9,547,425 | 8,308,720 | 8,265,745 | 6,643,573 | |
| 減：營業總成本 | 4,001,688 | -3.40% | 7,978,739 | 7,096,900 | 6,635,694 | 6,300,680 | |
| 其中:營業成本 | 1,656,535 | -14.98% | 3,636,604 | 3,288,338 | 3,110,936 | 2,657,134 | |
| 財務費用 | 97,588 | 176.69% | 95,480 | 137,247 | (10,833) | 188,184 | |
| 資產減值損失 | (54,291) | 85.97% | (122,874) | (117,176) | (70,604) | (13,928) | |
| 公允價值變動收益 | 32,700 | -148.65% | (69,493) | (100,248) | 5,201 | 299,808 | |
| 投資收益 | (12,095) | -15.46% | (28,720) | (62,652) | (75,205) | 147,151 | |
| 其中：對聯營企業和合營企業的投資收益 | (11,275) | -23.48% | (28,660) | (27,700) | (42,191) | (41,774) | |
| 營業利潤 | 541,255 | -43.47% | 1,470,789 | 1,124,540 | 1,547,171 | 868,399 | |
| 利潤總額 | 542,861 | -43.24% | 1,463,608 | 1,100,321 | 1,508,900 | 786,928 | |
| 減：所得稅費用 | 137,702 | -31.86% | 356,145 | 283,072 | 332,890 | 306,284 | |
| 淨利潤 | 405,159 | -46.29% | 1,107,463 | 817,249 | 1,176,009 | 480,644 | |
| 減：非控股權益 | (4,329) | -174.84% | (11,518) | (13,217) | 8,251 | (6,891) | |
| 股東淨利潤 | 409,488 | -45.30% | 1,118,981 | 830,466 | 1,167,759 | 487,535 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.280 | -46.15% | 0.770 | 0.570 | 0.810 | 0.340 | |
| 每股派息 (元) * | -- | -- | 0.250 | 0.200 | 0.240 | 0.100 | |
| 每股淨資產 (元) * | 6.459 | 10.64% | 5.903 | 5.286 | 4.925 | -- | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 10/09/2025 15:35 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
